

Cover Story
By Matthew Bin Han Ong
A federal judge has ruled against the Health Resources and Services Administration over provider access to 340B Drug Pricing Program discounts for orphan drugs.
By Matthew Bin Han Ong
In Brief


Funding Opportunities
Drugs & Targets


Trending Stories
- House passes three-year extension of ACA subsidies with bipartisan support
- The Mark Foundation names 2026 Emerging Leader Award recipients
- When “safe and effective” is not “reasonable and necessary”
We can curb excessive drug dosing and improve the quality of cancer care - Nancy Goodman: “Sen. Sanders says he cares about kids with cancer. I’m just asking him to show us.”
- Minimally invasive surgery lowers survival in cervical cancer, new studies show
- A radiation oncologist’s perspective: Why we need to accelerate early detection strategies for lung cancers











